Ventria Bioscience

Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The company's core technology is a plant-based protein production system called ExpressTec. Ventria's product pipeline is based on recombinant lactoferrin and lysozyme for use in medical foods, bioprocessing, cell culture and as a topical anti-infective. These proteins show promise as a supplement to oral rehydration therapy and to treat "C.difficile" infection because they inhibit "C.difficile", but promote the growth of healthy gut flora. Ventria invites other researchers to have access to its recombinant human lactoferrin and recombinant human lysozyme through a program called BioShare. The Company has operations in Kansas, North Carolina, California and Colorado. The Company recently completed construction of a bioprocessing facility in Kansas.

Regulatory Advantages

ExpressTec uses self-pollinating crops such as rice and barley to minimize the risk of gene flow normally associated with transgenic plants. Plant-produced proteins also offer advantages for cell culture and bioprocessing use because they replace animal derived components, which have become unpopular due to concerns about prion contamination. The use of food crops also allows for slightly less stringent purity standards when the product is processed for oral consumption.

News

On September 29, 2006, Kansas officials announced an agreement to bring Ventria’s new bioprocessing facility to Junction City, Kansas. Kansas Governor Kathleen Sebelius was very supportive of the agreement and was quoted as stating “I welcome Ventria Bioscience to Kansas and look forward to their contributions to the health of children worldwide.” The effort to attract Ventria to Kansas involved a number of players, including Governor Kathleen Sebelius, Secretary of Agriculture, Adrian Polansky, The Kansas Department of Commerce, Junction City and Geary County, Kansas Technology Enterprise Corporation (KTEC), KansasBIO, Kansas State University and Kansas Farm Bureau.

In February, 2007 the results of a new study found that electrolyte solution incorporating Ventria’s products, helped children recover faster from diarrhea. The study was published in the February issue of the Journal of Pediatric Gastroenterology and Nutrition, a leading medical journal. The results showed that the children receiving Ventria’s product recovered 30% faster, were more likely to recover from their diarrhea and were less likely to relapse into another episode. Ventria’s product comprises two proteins found naturally in breast milk. In the United States there are more than 1.5 million hospital visits for childhood diarrhea. Globally, childhood diarrhea is the second leading killer of children under the age of 5, claiming 2 million lives annually.

See also

*Pharming (genetics)

External links

* [http://www.ventria.com Ventria Bioscience Official site]